Clarity Pharmaceuticals (ASX:CU6) Accumulated Depreciation: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
31 GF Score
Price A$2.49
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Accumulated Depreciation?

Clarity Pharmaceuticals ASX:CU6 -3.11% 31 Accumulated Depreciation is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Clarity Pharmaceuticals's quarterly accumulated depreciation increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$-0.55 Mil) but then stayed the same from Jun. 2025 (A$-0.55 Mil) to Dec. 2025 (A$0.00 Mil).

Clarity Pharmaceuticals's annual accumulated depreciation increased from Jun. 2023 (A$-0.23 Mil) to Jun. 2024 (A$-0.38 Mil) and increased from Jun. 2024 (A$-0.38 Mil) to Jun. 2025 (A$-0.55 Mil).

Clarity Pharmaceuticals Accumulated Depreciation Related Terms

Clarity Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Accumulated Depreciation Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Accumulated Depreciation
-0.13 -0.23 -0.38 -0.55

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.38 0.00 -0.55 0.00
ASX:CU6
31GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$0.00 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Accumulated Depreciation of A$0.00 Mil as of Dec. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Accumulated Depreciation too high?
Clarity Pharmaceuticals' current Accumulated Depreciation is A$0.00 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Accumulated Depreciation compare to VRTX and REGN?
Clarity Pharmaceuticals' Accumulated Depreciation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Accumulated Depreciation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Accumulated Depreciation of A$0.00 Mil. The current Accumulated Depreciation is A$0.00 Mil. Clarity Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Accumulated Depreciation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
31GF Score

Get the complete analysis for ASX:CU6

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.49
Price